Annals of Oncology· @Annals_Oncology · X·· 1 天前评分70
正文 · 原文
📢 #ESMO26 concomitant paper - Atirmociclib and fulvestrant for patients with HR+/HER2– advanced/metastatic breast cancer who progressed on a prior cyclin-dependent kinase 4/6 inhibitor: primary analysis of the randomized FourLight-1 trial.
🔗https://tinyurl.com/449n4nu2
@hoperugo
101 浏览 · 0 赞 · 0 转发 · 0 回复
会议摘要
1842O按 Proffered paper 2: Breast cancer, early and advanced stage 对上
Efficacy and safety of atirmociclib (ATI) + fulvestrant (FUL) in patients (pts) with HR+/HER2– advanced/metastatic breast cancer (mBC) who progressed on prior CDK4/6 inhibitor (CDK4/6i) in a randomized phase 2 study (FOURLIGHT-1)
https://esmocongress.esmo.orgFOURLIGHT-1
https://esmocongress.esmo.org来源：Annals of Oncology · x.com